Nectin Therapeutics Enters Global, Exclusive License Agreement With Immunome; Immunome Receives Exclusive Rights To Panel Of Antibodies Targeting An Undisclosed Target
Portfolio Pulse from Benzinga Newsdesk
Nectin Therapeutics has entered into a global, exclusive license agreement with Immunome, granting Immunome exclusive rights to a panel of antibodies targeting an undisclosed target. Immunome will handle research, development, manufacturing, and commercialization, while Nectin will receive an upfront payment, milestones, and royalties.
July 25, 2024 | 11:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunome has secured exclusive global rights to a panel of antibodies from Nectin Therapeutics, which could enhance its product pipeline and market position. Immunome will manage all aspects of development and commercialization.
The exclusive license agreement provides Immunome with valuable assets that could significantly enhance its product offerings and market position. The responsibility for R&D, manufacturing, and commercialization indicates a substantial commitment and potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100